B.Riley Financial analyst Yuan Zhi reiterated a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report) today and set a price target of $18.00. The company's shares closed last Friday at $9.73.According to TipRanks, Zhi is an analyst with an average return of -16.7% and a 22.22% success rate. Zhi covers the Healthcare sector, focusing on stocks such as IVERIC bio, Azenta, and Actinium Pharmaceuticals.Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $27.60, a 183.66% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $53.00 price target.
https://www.tipranks.com/news/blurbs/b-riley-financial-remains-a-buy-on-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023 Plus de graphiques de la Bourse Actinium Pharmaceuticals